In one paragraphArticle in Journal of Huntington's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Yi Lin TayTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, Singapore, Singapore.ORCID 0009-0008-5175-4108 Sarah B ThomsonCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0000-0001-9407-1245 Silvia HnatovaTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, Singapore, Singapore.ORCID 0000-0001-9987-5306 Sherwin NgTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, Singapore, Singapore.ORCID 0009-0000-8809-7318 Si Rui TeoTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, Singapore, Singapore.
Ryan McCallumCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-0876-0595 Bernice SimTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, Singapore, Singapore.ORCID 0000-0002-6229-4425 Letizia TarantiniDepartment of Clinical Sciences and Community Health, EPIGET - Epidemiology, Epigenetics and Toxicology Laboratory, University of Milano, Milan, Italy.ORCID 0009-0003-9191-4237 Fei Li TaiTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, Singapore, Singapore.
Valentina BollatiDepartment of Clinical Sciences and Community Health, EPIGET - Epidemiology, Epigenetics and Toxicology Laboratory, University of Milano, Milan, Italy.
Marie LohTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, Singapore, Singapore.ORCID 0000-0003-3626-8466 Michael R HaydenCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0000-0001-5159-1419 Blair R LeavittCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-4532-766X Mahmoud A PouladiTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, Singapore, Singapore.ORCID 0000-0002-9030-0976 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
BackgroundGene silencing is widely recognized as a promising therapeutic approach for dominant monogenic disorders. Current silencing strategies, many of which are transient, utilize RNA interference. Gene silencing may also be achieved through directed epigenetic editing using a CRISPR/dCas9 effector fused to DNA methyltransferase 3A (dCas9-DNMT3A). We used this system to direct DNA methylation to
Indexed as
CRISPR-Cas SystemsDNA MethylationEpigenesis, GeneticGene SilencingHuntingtin ProteinHuntington DiseaseDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AEpigenome EditingHumansDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanHTT protein, humanHuntingtin ProteinCRISPR/Cas9DNA methylationepigenetic editinggene silencingHTTHuntington's disease
Identifiers
PMID41570009
PMCPMC13396422
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390